Replies to post #211921 on Innovation Pharmaceuticals Inc (IPIX)

[PlentyParanoid]

True, There is a difference.
Aprea says APR-246 reactivates the mutant type p53 and is mum about the wild type. IPIX says Kevetrin degrades the mutant type and activates the wild type.

But, simple me just can't figure which one is more beneficial based on this difference. It looks like ARP-246 would be fine only in cancers with high expressions of the mutant types and Kevetrin might be more widely applicable but in certain cancers not necessarily as potent as APR-246 can be. Dunno, been wrong before, maybe again.

However, what is getting clearer to me is this: Whichever gets first on the market can hardy keep the other out. They are too different to be covered with FDA's exclusivity rules. So, whichever company will be the first, the other will applaud loudly. Money-promise for both :)